News Focus
News Focus
icon url

ignatiusrielly35

08/18/25 10:05 AM

#498188 RE: Hoskuld #498185

I would accept 50% cash and 50% in stock of a quality mid-sized acquirer for a total of $14b.
icon url

tschussmann1

08/18/25 10:12 AM

#498191 RE: Hoskuld #498185

I do not think Anavex will sell out until FDA submission...or even FDA approval. If approved in Europe, the political pressure on the FDA to do the same will become quite strong. A3-71 favorable results would also obviously add value. Do you think Anavex could sell only the rights to Blarcamesine, and keep A3-71? If so, then they could issue a special dividend, and remain a smaller sized development company, but with enough cash to fund multiple trials simultaneously.
icon url

boi568

08/18/25 10:59 AM

#498209 RE: Hoskuld #498185

That's a good argument for Anavex to reject the buyout offer as premature. I would vote against that offer.